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An  international  expert  panel  was convened  to deliberate  the  management  of  azole-resistant  aspergillo-
sis.  In  culture-positive  cases,  in  vitro  susceptibility  testing  should  always  be performed  if antifungal
therapy  is intended.  Different  patterns  of  resistance  are  seen,  with  multi-azole  and  pan-azole  resis-
tance  more  common  than  resistance  to a single  triazole.  In  conﬁrmed  invasive  pulmonary  aspergillosis
due  to an  azole-resistant  Aspergillus,  the  experts  recommended  a switch  from  voriconazole  to  liposo-
®mal  amphotericin  B (L-AmB;  Ambisome ). In  regions  with  environmental  resistance  rates  of  ≥10%,  a
voriconazole–echinocandin  combination  or L-AmB  were  favoured  as  initial  therapy.  All experts  rec-
ommended  L-AmB  as core  therapy  for central  nervous  system  aspergillosis  suspected  to  be due  to an
azole-resistant  Aspergillus,  and  considered  the  addition  of a second  agent  with  the  majority  favouring
ﬂucytosine.  Intravenous  therapy  with  either  micafungin  or  L-AmB  given  as  either  intermittent  or  con-
tinuous  therapy  was  recommended  for chronic  pulmonary  aspergillosis  due  to a pan-azole-resistant
Aspergillus.  Local  and national  surveillance  with  identiﬁcation  of  clinical  and  environmental  resistance
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patterns,  rapid  diagnostics,  better  quality  clinical  outcome  data,  and  a greater  understanding  of  the factors
driving  or  minimising  environmental  resistance  are  areas  where  research  is urgently  needed,  as  well  as
the  development  of  new  oral  agents  outside  the  azole  drug  class.
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. Introduction
Aspergillus spp. are responsible for over 200,000 cases of invasive
spergillosis (IA) annually, and global estimates suggest that over
.2 million patients have chronic pulmonary aspergillosis (CPA)
nd 4.8 million suffer from allergic bronchopulmonary aspergillosis
ABPA) with most infections being caused by Aspergillus fumigatus
Denning et al., 2011b, 2013). Potentially fatal IA was  ﬁrst high-
ighted in 1970 by Young and colleagues who reported a series
f 98 patients with IA diagnosed at autopsy (Young et al., 1970).
herapeutic advances in cancer, organ transplantation and inﬂam-
atory/autoimmune disorders have inadvertently resulted an ever
ncreasing number of patients who are susceptible to IA (Brown
t al., 2012; Patterson, 2005). Furthermore, tuberculosis, espe-
ially in developing countries and the high incidence of chronic
bstructive pulmonary disease (COPD) contribute to the high rate of
PA, while the enormous worldwide burden of asthma contributes
o the rate of occurrence of ABPA (Brown et al., 2012; Denning
t al., 2011b). The mortality associated with IA remains signiﬁcant
espite treatment, i.e. 28.5% in a recent population-based study
Bitar et al., 2014).
. Clinical background
Since the 1990s, the therapeutic arsenal of antifungal agents
as expanded and the azole class of antifungal drugs has become
he mainstay for both the treatment and prevention of acute
nd chronic aspergillosis, especially among immunocompromised
osts (Herbrecht et al., 2002; Walsh et al., 2008; Maertens et al.,
011; Herbrecht et al., 2015). Mould-active azoles are the only
ystemic agents that can be used both orally and intravenously,
nd their use is associated with improved survival and quality of
ife in patients with aspergillosis (Neofytos et al., 2009). However,
. fumigatus isolates harbouring mutations to one or more azole
rugs, the latter denoting a multi-azole – or pan-azole – resis-
ant phenotype, have emerged among patients receiving chronic
zole therapy (Howard et al., 2009; Camps et al., 2012). Azole resis-
ance is commonly due to mutations in the cyp51A-gene, which
ncodes the target enzyme of antifungal azoles, and A. fumiga-
us colonies cultured from patients receiving long-term treatment
an represent different azole-resistant genotypes (Fig. 1). By con-
rast, studies from the Netherlands have shown a limited number
f resistance mechanisms to predominate in A. fumigatus isolates
ecovered from azole-naive patients and from the environment
Fig. 1). The main resistance mechanism elaborated by these iso-
ates consists of a substitution of leucine for histidine at codon 98
f the cyp51A-gene, in combination with a 34-bp tandem repeat
n the promoter region of this gene (TR34/L98H) (Snelders et al.,
008; van der Linden et al., 2011). Moreover, TR34/L98H has also
een reported in other European countries (van der Linden et al.,
015) and there is a fear that azole resistance could become a global
ublic health threat as fungal spores could disperse widely given
heir ability to cover thousands of miles in the air (Vermeulen et al.,
013; Chowdhary et al., 2013). This could explain why TR34/L98H
as also been reported in countries as far aﬁeld as China, the Mid-
le East, India, Africa, Australia and most recently Turkey (Lockhart
t al., 2011; Chowdhary et al., 2012; Seyedmousavi et al., 2013a;
howdhary et al., 2014b; Chowdhary et al., 2015; Kidd et al., 2015;hed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Özmerdiven et al., 2015). Surveillance studies from Europe, India
and Africa have also described the emergence of a new combination
of mutations (TR46/Y121F/T289A) in A. fumigatus that confers high
level resistance to voriconazole (Vermeulen et al., 2012; van der
Linden et al., 2013; Astvad et al., 2014; Chowdhary et al., 2014a;
Chowdhary et al., 2014b; Steinmann et al., 2015; van der Linden
et al., 2015; Lavergne et al., 2015). Alarmingly, azole-resistant iso-
lates recovered from clinical specimens, show a voriconazole MIC50
of 8 mg/l for isolates harbouring the TR34/L98H resistance mecha-
nisms and a MIC50 of >16 mg/l for TR46/Y121F/T289A isolates (van
Ingen et al., 2015). Even isavuconazole, which has only recently
been licensed for use showed reduced in vitro activity (Howard
et al., 2013b; Gregson et al., 2013) and reduced in vivo efﬁcacy
(Lepak et al., 2013a; Seyedmousavi et al., 2015) in A. fumigatus iso-
lates harbouring these resistance mechanisms. Isavuconazole MICs
were higher in strains with reduced susceptibilities to other tri-
azoles, mirroring changes in voriconazole susceptibility (Gregson
et al., 2013). Furthermore, there is a likelihood of treatment failure
and a fatal outcome when voriconazole is given as monotherapy in
accordance with the current recommendations to patients with IA
due to azole-resistant isolates harbouring one of these resistance
mechanisms (Walsh et al., 2008; Maertens et al., 2011; Snelders
et al., 2008; van der Linden et al., 2011; van der Linden et al., 2013;
Steinmann et al., 2015).
3. Role of the environment
There is mounting evidence that environmental exposure to
azole fungicides is driving the emergence of TR34/L98H and
TR46/Y121F/T289A resistance mechanisms (Verweij et al., 2009;
Snelders et al., 2012). Isolates harbouring these mechanisms of
resistance are widespread in the environment and have been
recovered from the environment and in hospitals located in sev-
eral European countries as well as India, the Middle-East and
Africa (Snelders et al., 2009; van der Linden et al., 2011; van
der Linden et al., 2013; Badali et al., 2013; Ahmad et al., 2014;
Chowdhary et al., 2014a; Chowdhary et al., 2014b; Bader et al.,
2015). Crucially, between 64% and 71% of patients with IA due
to an azole-resistant Aspergillus had never received an azole anti-
fungal and can be considered as azole-naive (van der Linden
et al., 2011; van der Linden et al., 2013). Furthermore, surveil-
lance studies indicate that the TR34/L98H and TR46/Y121F/T289A
resistance mechanisms were responsible for over 80% of aspergillo-
sis due to azole-resistant Aspergillus (Vermeulen et al., 2015;
Verweij and Leenstra, 2014), and therefore are an important
cause of disease in regions where environmental resistance is
found. Azole resistance complicates patient management with
respect to early detection and treatment, as clinical risk factors
for IA due to azole-resistant Aspergillus have not been identi-
ﬁed and the reported mortality rates are as high as 88% for
culture-positive patients (van der Linden et al., 2011; Steinmann
et al., 2015). However, there are no consensus guidelines avail-
able as yet and only limited clinical evidence is available to guide
physicians who  will be confronted with managing aspergillosis
due to azole-resistant Aspergillus.  Hence, an international expert
meeting was convened to discuss the clinical, diagnostic and
therapeutic implications of aspergillosis due to azole-resistant
Aspergillus.
32 P.E. Verweij et al. / Drug Resistance Updates 21–22 (2015) 30–40
Patient route 
Characteristics
• Long term azole therapy
• Mainly chronic cavitary pulmonary
aspergillosis 
• Point mutations in the Cyp51A-gene or 
unknown resistance mechanisms 
• Multiple resistance mechanisms may be 
found in dif ferent colonies from a 
single specimen 
Environmental route 
Characteristics
• Majority of patients are azole naïve 
• Patients with invasive aspergillosis and 
chronic aspergillus diseases  
• Only a few resistance mechanisms 
described 
• Resistance mechanisms consist of  
Cyp51A-substitution with  
transcriptional enhancer
Exposure of A. fumigatus in  
the environment to azole 
fungicides with activity  
against aspergilli
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. Participants and methods
The panel comprised 21 experts ((paediatric) infectious dis-
ases physicians, pulmonary physicians, medical microbiologists,
linical pharmacologists and haematologists) from 11 countries
ncluding Canada, the United States of America, India, Australia,
apan, and six European countries. A straightforward selection
rocedure was followed to compose the expert panel based on
hree criteria: professional experience (in the area’s of medi-
al mycology, knowledge in general and speciﬁcally relating to
zole-resistant Aspergillus and aspergillosis in general, including
ycological diagnosis, in vitro susceptibility testing, antifun-
al pharmacology, clinical experience in the management of
spergillosis), independency, and ability to work in a group,
ccording to European standards (http://ec.europa.eu/europeaid/
valuation/methodology/examples/too pan res en.pdf). The panel
iscussions were chaired by PEV and JPD. Their role was  to guide
he study panel, propose working arrangements, record ﬁndings,
ncourage contributions, and to facilitate debates. Three clinical
cenarios prepared by the chairpersons were presented to the panel
see web extra material for details of the cases). These case dis-
ussions generated care pathways that captured critical clinical
ecision-making nodes (see Figs. 2 and 3). Given the paucity of clin-
cal evidence currently available, the aim was neither to formulate
ractice guidelines nor to achieve a complete consensus but rather
o provide practical recommendations for clinicians pending better
uality evidence. Differences in opinion were captured by voting.
inally, areas of research and unmet needs were identiﬁed.
. Invasive pulmonary aspergillosisDiagnosis among patients at risk of invasive pulmonary
spergillosis (IPA) is often based solely on the detection of
spergillus galactomannan antigen in clinical specimens, and iden-
iﬁcation of characteristic abnormalities on computed tomographicy known characteristics (Verweij et al., 2009). Blue indicates azole-susceptible and
e reader is referred to the web version of this article.)
(CT) scan. Unfortunately, conventional culture remains insensitive
even though isolation of Aspergillus followed by in vitro suscepti-
bility testing is usually required to detect azole resistance. Direct
detection of resistance mutations by polymerase chain reaction
(PCR) from clinical specimens may  expedite the identiﬁcation of
resistance. However, PCR-based assays are not standardised or val-
idated, are currently restricted to reference laboratories and the
sensitivity of these tests as well as the spectrum of resistance mech-
anisms detected are a matter of concern (van der Linden et al., 2010;
Denning et al., 2011a; Zhao et al., 2013).
Consequently, discussion regarding the management of patients
with aspergillosis due to azole-resistant Asperillus focused on
culture-based diagnostic and therapeutic aspects, informed by the
local epidemiology or clinical and environmental azole resistance.
5.1. Microbiological diagnosis
All experts agreed that establishing a microbiological diagnosis
was critical to guiding therapy, especially in regions or insti-
tutions with high rates of azole resistance. Samples should be
obtained prior to therapy and tested using culture-based methods.
In practice, this means obtaining appropriate respiratory samples
since Aspergillus is rarely recovered from blood cultures. All iso-
lates of Aspergillus recovered from clinical specimens from patients
who will receive antifungal treatment should be identiﬁed to
species complex level, by the local clinical microbiology labora-
tory or through referral to a specialist laboratory (Schelenz et al.,
2015). Drug susceptibility testing should also be performed, and
the results should be reported ideally within 72 h of recovery of A.
fumigatus. Whenever possible, it was advised to test different, up to
ﬁve, colonies as different azole susceptibility phenotypes might be
present in a single culture. If an azole-resistant A. fumigatus is iso-
lated, molecular identiﬁcation of the resistance mechanism should
also be performed for epidemiological reasons although this should
not delay MIC  determination nor treatment modiﬁcation.
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Patient at risk for 
IA 
Clinical decision to treat IA 
Initial therapy with VCZ 
A. fumigatus
cultured 
Wild type 
susceptibility 
Continue 
VCZ 
Azole
resistant 
Avoid azole monotherapy
Switch to L-AmB
Or 
VCZ+echinocandin
Or 
Other non-azole based 
regimen (i.e,  echinocandin) 
Determine MIC 
•  In region with  azole resistance 
•  Rapid (  72 hours) – phenotype 
•  Test multiple colonies (  5) 
Determine resistance mechanism 
(epidemiology) 
Factors to consider 
•  Anticipated duration of   
neutropenia or immunosuppression
•  Potential drug interactions 
• Monitor drug exposure 
• Organ dysfunction 
• Prior antifungal use 
• Results of antimicrobial 
susceptibility testing 
• Severity of illness 
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oriconazole.
To-date, susceptibility testing of azole-resistant A. fumigatus
solates has been primarily generated using the CLSI M38-A2
icrodilution method and EUCAST microdilution technique (CLSI,
008; Rodriguez-Tudela et al., 2008; Arendrup et al., 2013).
hese methods allow azole-resistant phenotypes in A. fumiga-
us to be detected and have enabled epidemiological cut-off
Patient at risk for 
IA 
Clinical decision to 
treat IA 
VCZ+Ecand
Or 
L-AmB
Evidence of azol e
resistance  
Evidence of wild  
type
Culture n
Susceptib
Adjust therapy 
according to  
phenotype / 
genotype 
Convert to 
voriconazol e
unless reasons  
not to 
After 2 
Trial de
Convert
With co
(TDM/G 
ig. 3. Management of patients with clinical suspicion of IPA in regions with environmen
,  VCZ, voriconazole; Ecand, echinocandin; TDM, therapeutic drug monitoring; GM,  galace environment. IA, invasive aspergillosis; L-AmB, liposomal amphoptericin B, VCZ,
values (ECOFF/ECV) to be established for itraconazole (1 mg/l),
voriconazole (1 mg/l) and posaconazole (0.25 mg/l). A preliminary
ECOFF/ECV for isavuconazole (CLSI: 1 mg/l; EUCAST 2 mg/l) has also
recently been proposed (Espinel-Ingroff et al., 2013; Howard et al.,
2013b). Clinical breakpoints for resistance of >2 mg/l have been
established for itraconazole and voriconazole and >0.25 mg/l for
Know your local epidemiology 
Rate of environmental resistance 10% 
Consider risk non-Aspergillus
Differences in efficacy 
Epidemiology of resistance mechanisms 
egative 
ility unknown 
weeks and clinically improving 
escalation can be considered 
 to voriconazole (or posaconazole) 
ntinued careful monitoring 
M/other markers/imaging 
tal resistance of ≥10%. IA, invasive aspergillosis; L-AmB, liposomal amphoptericin
tomannan.
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osaconazole (Arendrup et al., 2013). Commercial methods of sus-
eptibility testing are available but currently no studies have fully
alidated their use for detecting azole resistance in aspergillus. If
he appropriate technology is not available in a given centre, the
anel recommended that up to ﬁve colonies of the isolate should
e sent to a reference laboratory for in vitro susceptibility testing.
torage of all the primary isolation plates or subcultures and the
esults of molecular studies should be considered for future test-
ng, including epidemiological investigations, in order to track the
evelopment of acquired resistance in patients on long term azole
herapy, or to identify the possible cause of clinical failure in the
ame patient or in other patients.
. Choice of antifungal therapy in regions with no/minimal
zole resistance
In regions, institutions or departments with reliable data show-
ng minimal (<5%) or no azole resistance, all experts agreed that
ational or international therapy guidelines should be followed;
hese currently recommend voriconazole as initial therapy for
lmost all patients with suspected IA (Table 1) (Herbrecht et al.,
002; Walsh et al., 2008; Maertens et al., 2011; Lortholary et al.,
011). All experts but one agreed that voriconazole monother-
py should be discontinued if a voriconazole-resistant A. fumigatus
as subsequently identiﬁed. The dissenting expert argued that
he decision should also be based on the patient’s clinical con-
itions, with a patient who was otherwise improving possibly
taying on voriconazole monotherapy; this opinion was also based
n the absence of clinical data demonstrating a clear-cut correla-
ion between in vitro resistance and clinical outcome. The merit of
sing voriconazole combination therapy or switching to an alterna-
ive agent was also debated. Combined therapy with voriconazole
lus anidulafungin showed a trend towards improved outcome
ompared with voriconazole monotherapy for patients with IA
Marr et al., 2015), but in vitro susceptibility testing results of
ulture-positive patients were not reported and azole resistance
ost probably accounted for only a minority of patients, if any.
lthough preclinical data suggest that the additive action of an
zole-echinocandin combination might render an azole-resistant A.
umigatus strain more susceptible (Jeans et al., 2012; Seyedmousavi
t al., 2013b; Lepak et al., 2013b), no clinical evidence exists to
upport this combination in IA due to azole-resistant Aspergillus.
chinocandin monotherapy might be an alternative, as the in vitro
ctivity of echinocandins against A. fumigatus appear unaffected by
he presence of an azole resistance mechanism (van Ingen et al.,
015). Caspofungin has been shown to be efﬁcacious for patients
ith IA (Viscoli et al., 2009; Herbrecht et al., 2010; Cornely et al.,
011), but the success rates were disappointing with outcomes of
0% or less. One experimental study has shown comparable effec-
iveness of L-AmB against IA due to wild-type and azole-resistant
spergillus, indicating that azole resistance does not diminish the
fﬁcacy of L-AmB (Seyedmousavi et al., 2013c). Thus, for azole-
esistant strains, there was unanimous agreement that treatment
hould be switched to L-AmB, depending on the patient and on
nstitutional variables such as cost (Fig. 2).
. Choice of antifungal therapy in regions with
pidemiological evidence of azole resistance in
nvironmental isolates
Although azole resistance is increasingly being recognised,
esistance rates vary considerably between regions and institutions
Vermeulen et al., 2013; Chowdhary et al., 2013). All experts con-
idered that the most current epidemiological data from national
nd local surveillance programs should be used to guide the choiceUpdates 21–22 (2015) 30–40
of initial therapy. Levels of environmental azole resistance of 5%
to <10% and ≥10% were chosen as the basis for panel discussion
regarding the choice of initial antifungal therapy prior to suscepti-
bility results or in the absence of culture.
7.1. Azole resistance rate due to environmental mechanisms of
>10%
A >10% level of azole resistance was considered by the majority
of experts to represent a “high level of resistance” which should
prompt a re-evaluation of voriconazole monotherapy for primary
treatment. The panel advocated either a combination of voricona-
zole plus an echinocandin or L-AmB as initial empiric therapy in
regions, institutions or departments with this level of resistance
pending susceptibility data (Fig. 3). Subsequent therapy would then
be dependent upon the results of susceptibility testing, drug mon-
itoring results and clinical considerations, as follows:
a) IA due to azole-resistant Aspergillus conﬁrmed: ongoing therapy
should be with an agent to which the organism is susceptible.
b) IA due to azole-susceptible Aspergillus conﬁrmed: all experts
would continue with voriconazole monotherapy. A minority of
experts who chose L-AmB as initial therapy advocated a period
of overlap, i.e. continuing with L-AmB until therapeutic levels
of voriconazole were achieved. Similar views were expressed
by those who  chose the voriconazole-echinocandin combina-
tion as initial therapy, with discontinuation of the echinocandin
once voriconazole levels were adequate. Posaconazole was
considered a reasonable alternative when voriconazole was
unsuitable.
(c) Unknown susceptibility (due to culture negativity): the major-
ity of experts who chose L-AmB as initial therapy supported
a cautious de-escalation to voriconazole or posaconazole
monotherapy after 2 weeks of L-AmB provided the patient was
responding clinically. This approach may  appear to contradict
the rationale for using L-AmB as initial empiric therapy but it
was  regarded as a pragmatic course of action for a patient who
had survived the acute phase of the infection and had achieved
clinical stability. This would also allow the use of oral main-
tenance therapy and discharge to the outpatient setting. Even
in the high-level resistance setting, there would still be a high
probability that the isolate was azole susceptible. All experts
advocated close clinical follow-up, with therapeutic drug mon-
itoring (TDM), relevant biomarkers, and imaging to monitor
progress.
7.2. Resistance rate due to environmental mechanisms of 5% to
<10%
In contrast to the previous scenario, opinions were more divided
regarding choice of initial therapy in regions with resistance preva-
lence rates of 5% to <10%. Approximately half the panel advocated
voriconazole monotherapy and the remainder favoured a combina-
tion of voriconazole and an echinocandin or L-AmB monotherapy.
Discussion focussed on survival rates shown in studies using
voriconazole, L-AmB and caspofungin (all given as monother-
apy), or the voriconazole–anidulafungin combination. Although
voriconazole was  shown to be more effective than conventional
AmB, patients starting with this drug could switch to therapy
with other licensed agents, including lipid-formulations of AmB,
as dictated by the occurrence of toxic effects or a lack of response
(Herbrecht et al., 2002). As no head-to-head comparative clini-
cal study between L-AmB and voriconazole has been performed,
some experts referred to numerous post-marketing observational
reports that have indicated that the effectiveness of voriconazole
in the treatment of IA is 15–20% higher than for all amphotericin
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Table  1
Recommendations from national and international guidelines on anti-Aspergillus ﬁrst line drugs (B.E. de Pauw and J.P. Donnelly, unpublished).
Drugs IDSA ECIL UK Italy Germany Australia
Conventional AmB  D D D D D AII
L-AmB AI BI AI BI AII BI
ABLC  BII BII BII BII
ABCD  D BIII D BIII
Itraconazole CIII BII
Voriconazole AI AI AI AI AI AI
Posaconazole D
Caspofungin CII AI BII BII BII
A d com
B
P
L
f
c
8
f
o
C
i
a
g
e
t
A
c
K
t
b
o
r
t
a
r
r
d
f
w
c
C
s
C
t
i
T
a
o
b
o
t
a
G
t
e
t
m
AMicafungin 
mB, amphotericin B; L-AmB, liposomal amphotericin B; ABLC, amphotericin B lipi
 and echinocandin agents (Nivoix et al., 2008; Upton et al., 2007;
agano et al., 2010; Baddley et al., 2010; Perkhofer et al., 2010;
ortholary et al., 2011). Concern was expressed that a shift away
rom voriconazole therapy due to increasing azole resistance may
ome at the expense of lower global efﬁcacy.
. CNS invasive aspergillosis
Central nervous system (CNS) IA, as with other extrapulmonary
orms of IA, is uncommon but it is the most feared complication
wing to the high mortality rate (Kourkoumpetis et al., 2012). The
NS and the eyes are considered sanctuary sites, because achiev-
ng adequate drug concentrations is challenging. Although there
re limited data on the treatment of these infections, international
uidelines recommend voriconazole as ﬁrst-line therapy (Walsh
t al., 2008) given its favourable pharmacokinetic properties in
he brain and greatly improved survival rates (Kethireddy and
ndes, 2007; Schwartz et al., 2005). When indicated, neurosurgi-
al intervention may  also improve prognosis (Coleman et al., 1995;
ourkoumpetis et al., 2012).
In the context of appreciable rates of environmental azole resis-
ance in A. fumigatus,  all experts agreed that biopsy samples should
e rapidly obtained for microbiological diagnosis, including the use
f non-culture-based techniques such as PCR, by a reference labo-
atory (Kourkoumpetis et al., 2012; Reinwald et al., 2013), rather
han relying on characteristic imaging and non-culture-based tests.
Discussion focused on the choice of antifungal therapy for
 patient with presumed CNS aspergillosis caused by an azole-
esistant A. fumigatus isolated from a non-sterile site such as the
espiratory tract. Treatment with voriconazole of CNS aspergillosis
ue to an azole-susceptible Aspergillus, has been shown to con-
er the most favourable clinical response (Schwartz et al., 2005),
ith other agents such as the polyenes being considered less efﬁ-
acious (Schwartz et al., 2007). Voriconazole achieves the highest
SF drug levels of any of the azoles with anti-aspergillus activity
ince itraconazole and posaconazole are virtually undetectable in
SF (Kethireddy and Andes, 2007), although brain tissue concen-
rations with all these agents are adequate for successful therapy,
f systematic exposure is in the accepted range (Felton et al., 2014).
he same is true for conventional and lipid-formulations of AmB
nd for the echinocandins, thus severely limiting the treatment
ptions in patients when the use of voriconazole is precluded. Rab-
it models of infection indicated that the absolute concentrations
f L-AmB in the brain were signiﬁcantly higher, 3.6- to 5.2-fold,
han for conventional AmB, amphotericin B lipid complex (ABLC)
nd amphotericin B colloidal dispersion (ABCD) (Lee et al., 1994;
roll et al., 2000). These differences in brain parenchymal concen-
rations favour the L-AmB formulation and were associated with
nhanced therapeutic efﬁcacy in this model. Therefore, based on
hese limited pharmacokinetic and pharmacodynamic animal data,
ost experts preferred L-AmB over conventional AmB, ABLC and
BCD for treatment of CNS infection.BIII
plex; ABCD, amphotericin B colloidal dispersion.
There are few reported cases of CNS aspergillosis due to
azole-resistant Aspergillus and most patients received combination
antifungal therapy (van der Linden et al., 2009; Howard et al., 2009;
van der Linden et al., 2010; van der Linden et al., 2011; van der
Linden et al., 2013). Survival was  uniformly poor, with the excep-
tion of a single patient who  received a combination of L-AmB,
caspofungin and posaconazole and survived (van der Linden et al.,
2010).
All experts indicated that they would use L-AmB as core ther-
apy in cases of CNS aspergillosis suspected or conﬁrmed to be
due to an azole-resistant Aspergillus,  with L-AmB being adminis-
tered at a high daily dose (i.e., 5 mg/kg) in accordance with current
international guidelines (Walsh et al., 2008). There was unanimous
agreement in favour of adding a second drug, with the majority sup-
porting ﬂucytosine (5-FC) and the remaining experts supporting
either voriconazole or an echinocandin. Most experts discouraged
the use of intrathecal or intralesional antifungal therapy for the
treatment of CNS aspergillosis, except in rare circumstances.
The combination of AmB  and 5-FC was  used for the manage-
ment of CNS aspergillosis before voriconazole became available in
2002 (Denning and Stevens, 1990). 5-FC achieves good CSF-levels
(Block and Bennett, 1972), and experimental models of IA have
shown efﬁcacy of 5-FC alone and in combination with AmB  (Arroyo
et al., 1977; Verweij et al., 2008). Although 5FC has generally shown
no in vitro activity against A. fumigatus when tested at pH 7.0 the
majority of isolates showed low MIC  values when tested at pH 5.0
(Verweij et al., 2008). A murine model of disseminated IA showed
low MICs of 5-FC at a pH of 5.0 correlated with improved survival
(Verweij et al., 2008). These experiments were performed with wild
type A. fumigatus isolates and, to-date, no in vitro susceptibility
data are available for 5-FC against azole-resistant A. fumigatus iso-
lates highlighting an area for future research. The use of 5-FC for
the management of IA is controversial due to the paucity of clini-
cal studies supporting its use in combination therapy (Burch et al.,
1987; Verweij et al., 2008). However, the combination of 5-FC with
AmB  has been considered to have some role in difﬁcult Aspergillus
infections (Denning and Stevens, 1990).
Although the in vitro activity of echinocandins against azole-
resistant A. fumigatus isolates is comparable to that of wild type
isolates (van Ingen et al., 2015), echinocandins only attain very
low drug levels in the CSF of adult patients and are not recom-
mended for CNS IA (Denning, 2003; Jans et al., 2013), despite the
fact that occasional patients have responded to therapy (Maertens
et al., 2004).
9. Other types of aspergillosis
Patients with CPA, aspergillus bronchitis, ABPA, and severe
asthma with fungal sensitisation (SAFS) often respond to antifungal
therapy. While discussion mainly focussed on patients with CPA,
the experts considered that the same management principles also
applied to other conditions. CPA is associated with progressive lung
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estruction and a 5-year mortality rate of 50–85% (Nakamoto et al.,
013; Ohba et al., 2012). A recent longitudinal study showed that
ong-term antifungal therapy in CPA improved the quality of life
nd prevented progression (Al-Shair et al., 2013; Agarwal et al.,
013). Oral therapy with itraconazole or voriconazole is recom-
ended for patients with CPA due to azole-susceptible Aspergillus
Walsh et al., 2008). However, patients receiving long-term azole
herapy are at risk for the selection of azole-resistant A. fumigatus,
specially for difﬁcult-to-treat diseases such as chronic cavitary
ulmonary aspergillosis, and when an aspergilloma is present
Verweij et al., 2009; Camps et al., 2012; Howard et al., 2013a).
zole resistance is common in this patient group, the mechanisms
f resistance are extremely diverse and they are primarily caused
y non-environmental mutations (Howard et al., 2009). In light
f this information, the panel discussed strategies by which the
anagement of patients with CPA could be improved.
.1. Diagnostic issues
Azole resistance is frequently under-recognised or inadequately
iagnosed in CPA (Denning et al., 2011b). One study using an ultra-
ensitive real-time PCR assay detected resistance mutations in 55%
f culture-negative, Aspergillus PCR positive respiratory samples
Denning et al., 2011a). Although this was not conﬁrmed in a sub-
equent study using the same methodology and a similar patient
ohort (Zhao et al., 2013), the panel agreed that diagnosis could be
mproved by: (a) periodic culture and susceptibility testing of all
solates from patients on long-term azole therapy; (b) the standard
se of high volume sputum culture (Fraczek et al., 2014), with early
creening of resistance using azole-containing agar plates possibly
eing useful; (c) testing of multiple colonies from sputum cultures;
nd using primary plates to detect resistance, and (d) ensuring that
dentiﬁed isolates are sent to a reference centre for conﬁrmation of
he resistance mechanism.
.2. Treatment issues
Evidence shows that suboptimal azole exposure in patients on
ong-term therapy is a powerful predictor for the emergence of
esistance (Howard et al., 2009; Escribano et al., 2012). Suboptimal
xposure may  result from inadequate dosing, poor adherence, or
harmacokinetic drug–drug interactions, and may  be more likely if
he burden of infection is high, for example when an aspergilloma
s involved (Howard et al., 2009). Thus, the panel recommended
he following measures: (a) TDM to ensure sufﬁcient azole expo-
ure; and (b) patient education, emphasising the importance of
dministration issues and adherence.
CPA requires long-term oral treatment. As azoles are the only
ral agent available, they should remain ﬁrst line therapy regardless
f environmental resistance rates. If an individual patient devel-
ps resistance to one or two azoles, the panel agreed that therapy
hould be switched to an alternative azole agent to which the
rganism is susceptible. In the event of pan-azole resistance devel-
pment (i.e. to itraconazole, voriconazole, posaconazole), switch
o intravenous therapy with a non-azole agent was  strongly rec-
mmended. Randomised controlled trials in Japan have shown
hat intravenous micafungin is associated with similar short-term
linical efﬁcacy to voriconazole and to caspofungin in the treat-
ent of CPA (Kohno et al., 2010; Kohno et al., 2011; Kohno et al.,
013). Micafungin is most intensively studied in CPA with over 180
atients reported in the literature (Kohno et al., 2004; Izumikawa
t al., 2007; Yasuda et al., 2009; Kohno et al., 2010; Kohno et al.,
011; Kohno et al., 2013), compared to less than 50 CPA patients
reated with caspofungin (Kohno et al., 2013; Keir et al., 2014). The
linical response rates were between 42.4% and 78%. A duration of
 weeks therapy is the minimum demonstrated to be effective andUpdates 21–22 (2015) 30–40
many patients have been treated for up to 90 days, with beneﬁt.
Evidence that supports the use of anidulafungin for the treatment
of CPA is currently lacking.
Limited data suggest that L-AmB may be considered as an alter-
native to azole therapy (Newton et al., 2013). Surgical resection
with intravenous antifungal perioperative cover was considered
an option for patients with localised azole-resistant disease (Farid
et al., 2013). Since CPA generally requires long-term therapy,
patients should be carefully monitored for adverse events, includ-
ing drug toxicities or intolerance.
Non-azole oral agents and other therapeutic approaches were
also discussed. Limited data regarding the use of terbinaﬁne are
conﬂicting, and further research is needed to establish the utility of
5-FC. Nebulised AmB  may  be suitable for some patients with ABPA
and SAFS but its use is limited by tolerability, a contraindication
for patients with poor pulmonary function, and practical consid-
erations (Chishimba et al., 2014). Intracavitary instillation of AmB
may  be of beneﬁt for some patients but this treatment should only
be done by an expert.
10. Research agenda and unmet medical needs
The experts identiﬁed a number of areas that require further
research and/or represent unmet medical needs.
10.1. Epidemiology and diagnosis
Further research is required to establish the environmental
prevalence and clinical incidence of azole resistance in A. fumiga-
tus. These efforts would be facilitated by local and multi-national
surveillance programs, and by active reporting of azole-resistant
aspergillosis to public health authorities. There is an urgent need
for outcome data documenting clinical success, as well as failure,
through European and international registries, pending clinical trial
initiatives. In addition, there is a need for a better understand-
ing of the factors driving environmental resistance, together with
identiﬁcation of the practices that can minimise the emergence
and persistence of resistance. From a laboratory perspective, vali-
dation of commercial methods that enable the rapid and accurate
detection of resistance are urgently required, including primary
screening agar plates for in vitro susceptibility testing and MIC
determination, and methods for phenotypic and genotypic iden-
tiﬁcation. Recently, a commercial PCR assay became available,
which enables the detection of two azole resistance mechanisms
(TR34/L98H and TR46/Y121F/T289A) in BAL-ﬂuid and serum (Asper-
Genius, PathoNostics, The Netherlands). The performance of the
PCR-assay is promising in BAL-ﬂuid as it detects and differentiates
wild-type from resistant strains, even if BAL-ﬂuid cultures remain
negative (Chong et al., 2015). The sensitivity of the assay to detect
resistance mutations in serum is suboptimal, as the Cyp51A-gene
is a single copy gene (White et al., 2015).
10.2. Treatment
Investment in drug development for oral alternatives to the
azole class of antifungals is needed since we  are at risk of los-
ing these important drugs (Denning and Bromley, 2015). Clinical
trials are also required to ﬁll gaps in our knowledge regarding
existing antifungal agents such as trials to determine the compar-
ative efﬁcacy of azoles and L-AmB, or azoles in combination with
L-AmB. Improved in vivo and in vitro models designed to evalu-
ate pharmacokinetic/pharmacodynamic proﬁles, especially of new
drug formulations (e.g. posaconazole), would provide data to fur-
ther validate clinical breakpoints and guide therapy. The argument
for funding these research proposals would be strengthened by
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nalysing the health and economic consequences of azole resis-
ance.
1. Summary
Our current understanding of the emergence of azole resistance
n A. fumigatus is still limited, as is our clinical experience of treating
ases with aspergillosis due to azole-resistant Aspergillus.  Nev-
rtheless, emerging resistance associated with very poor clinical
utcomes was the impetus for these practical recommendations,
hich, of necessity, were based on the best available evidence sup-
lemented with expert opinion informed by clinical experience
nd the results of preclinical research. Opinions differed in some
nstances, but the care pathways proposed may  provide some guid-
nce to those confronted with aspergillosis due to azole resistant
spergillus.
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